Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers synthesized silver nanoparticles using an extract from Mitracarpus scaber and found them to have significant hepatoprotective and anti-hyperplastic effects in rats, suggesting potential for treating liver injury and benign prostatic hyperplasia.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

In this study, researchers found that young men with androgenic alopecia exhibited significantly higher mRNA levels of 5α-reductase isozymes and changes in prostate cancer-related genes, which could explain varying responses to treatment and guide future therapies.

This study found that prostate cancer aggressiveness in men with obesity is associated with changes in age, BMI, testosterone, and estradiol levels, and that adipocyte-secreted molecules increase cancer cell aggressiveness in vitro.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

In this study, D-004 did not affect androgen-dependent development in rats exposed in utero, while finasteride caused significant changes in male offspring's androgen-dependent tissues.

This study found that silver nanoparticles synthesized using Mitracarpus scaber extract showed potential hepatoprotective and anti-hyperplastic effects in rats, suggesting novel therapeutic strategies for managing liver injury and benign prostatic hyperplasia.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study identified the N-(iodopropenyl) derivative 13 as a promising candidate for development as a radioiodinated androgen receptor ligand due to its binding affinity.

This article reviews the safety of finasteride by examining existing literature and does not report new findings, highlighting the ongoing controversies regarding its adverse effects.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study observed that intrauterine and early postnatal exposure to finasteride affected prostatic development in Mongolian gerbils, with significant sex-based differences, particularly higher alterations in female prostates.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.

In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study observed that in hormone-starved prostate cancer cells, the androgen 5alpha-dihydrotestosterone rapidly induces matriptase activation and shedding, which involves androgen receptor signaling and requires both transcription and protein synthesis.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

This study found that the gut microbiota composition in patients with post-finasteride syndrome differs significantly from healthy controls, with reduced diversity and specific microbial changes, suggesting a potential diagnostic marker and therapeutic target.

This study observed that men with vertex androgenetic alopecia at age 40 had a higher risk of early-onset prostate cancer, suggesting a potential link between the conditions.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

This abstract reports funding sources for ongoing research and does not present any study results.

This study concluded that 16β-methyl-17α-benzoyloxypregnen-4-en-3,20-dione may be a promising treatment for androgen-dependent diseases and epilepsy due to its antioxidant effects and impact on GABAergic and serotonergic metabolism in rats.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.

This review discusses the potential use of prostate specific antigen as a diagnostic marker for hyperandrogenism in polycystic ovary syndrome but reports no new clinical results and calls for further research.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.